Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 5, 2006, Pages 500-508

  Heusser, Karsten ^a,b   Tank, Jens ^a,b   Diedrich, Andre ^a,b   Engeli, Stefan ^a,b   Klaua, Susanne ^a,b   Krüger, Nadine ^a,b   Strauss, Anke ^a,b   Stoffels, Gritt ^a,b   Luft, Friedrich C ^a,b   Jordan, Jens ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PLACEBO; SIBUTRAMINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; BODY MASS; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART RATE; HUMAN; MALE; OBESITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; SYMPATHETIC NERVE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

ADULT; BAROREFLEX; BLOOD PRESSURE; CROSS-OVER STUDIES; CYCLOBUTANES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; OBESITY; VASOMOTOR SYSTEM;

EID: 33646195269     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.02.002     Document Type: Article

References (30)

1. Stevens V.J., Obarzanek E., Cook N.R., Lee I.M., Appel L.J., Smith-West D., et al. Long-term weight loss and changes in blood pressure. results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 134 (2001) 1-11
2. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jain A.K., Mendel C.M., et al. Sibutramine produces dose-related weight loss. Obes Res 7 (1999) 189-198
3. James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356 (2000) 2119-2125
4. Luque C.A., and Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 440 (2002) 119-128
5. Walsh K.M., Leen E., and Lean M.E. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 23 (1999) 1009-1015
6. Hansen D.L., Toubro S., Stock M.J., MacDonald I.A., and Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 23 (1999) 1016-1024
7. Kahan T., Hjemdahl P., and Dahlof C. Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle. Acta Physiol Scand 122 (1984) 571-582
8. Jordan J., Scholze J., Matiba B., Wirth A., Hauner H., and Sharma A.M. Influence of sibutramine on blood pressure. evidence from placebo-controlled trials. Int J Obes Relat Metab Disord 29 (2005) 509-516
9. Szabo B., Karsch V., and Starke K. Effects of inhibitors of neuronal uptake of 5-HT on sympathetic cardiovascular regulation. J Cardiovasc Pharmacol 20 (1992) 99-107
10. Penttila J., Syvalahti E., Hinkka S., Kuusela T., and Scheinin H. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 154 (2001) 343-349
11. Eisenhofer G., Saigusa T., Esler M.D., Cox H.S., Angus J.A., and Dorward P.K. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol 260 (1991) R824-R832
12. Esler M.D., Wallin G., Dorward P.K., Eisenhofer G., Westerman R., Meredith I., et al. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol 260 (1991) R817-R823
13. Birkenfeld A.L., Schroeder C., Boschmann M., Tank J., Franke G., Luft F.C., et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106 (2002) 2459-2465
14. Schroeder C., Tank J., Boschmann M., Diedrich A., Sharma A.M., Biaggioni I., et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 105 (2002) 347-353
15. Tank J., Schroeder C., Diedrich A., Szczech E., Haertter S., Sharma A.M., et al. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation 107 (2003) 2949-2954
16. Grassi G., Seravalle G., Cattaneo B.M., Bolla G.B., Lanfranchi A., Colombo M., et al. Sympathetic activation in obese normotensive subjects. Hypertension 25 (1995) 560-563
17. Grassi G., Seravalle G., Dell'Oro R., Turri C., Bolla G.B., and Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 36 (2000) 538-542
18. Narkiewicz K., Kato M., Pesek C.A., and Somers V.K. Human obesity is characterized by a selective potentiation of central chemoreflex sensitivity. Hypertension 33 (1999) 1153-1158
19. Sherwood A., Allen M.T., Fahrenberg J., Kelsey R.M., Lovallo W.R., and van Doornen L.J. Methodological guidelines for impedance cardiography. Psychophysiology 27 (1990) 1-23
20. Tank J., Diedrich A., Schroeder C., Stoffels M., Franke G., Sharma A.M., et al. Limited effect of systemic beta-blockade on sympathetic outflow. Hypertension 38 (2001) 1377-1381
21. Willemsen J.J., Ross H.A., Jacobs M.C., Lenders J.W., Thien T., Swinkels L.M., et al. Highly sensitive and specific HPLC with fluorometric detection for determination of plasma epinephrine and norepinephrine applied to kinetic studies in humans. Clin Chem 41 (1995) 1455-1460
22. Willemsen J.J., Ross H.A., Wolthers B.G., Sweep C.G., and Kema I.P. Evaluation of specific high-performance liquid-chromatographic determinations of urinary metanephrine and normetanephrine by comparison with isotope dilution mass spectrometry. Ann Clin Biochem 38 (2001) 722-730
23. Birkenfeld A.L., Schroeder C., Pischon T., Tank J., Luft F.C., Sharma A.M., et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients-sibutramine and blood pressure. Clin Auton Res 15 (2005) 200-206
24. Preiss G., and Polosa C. Patterns of sympathetic neuron activity associated with Mayer waves. Am J Physiol 226 (1974) 724-730
25. Unnerstall J.R., Kopajtic T.A., and Kuhar M.J. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system. analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res 319 (1984) 69-101
26. Tank J., Diedrich A., Szczech E., Luft F.C., and Jordan J. Alpha-2 adrenergic transmission and human baroreflex regulation. Hypertension 43 (2004) 1035-1041
27. Jordan J., Tank J., Shannon J.R., Diedrich A., Lipp A., Schroder C., et al. Baroreflex buffering and susceptibility to vasoactive drugs. Circulation 105 (2002) 1459-1464
28. Ersoz H.O., Ukinc K., Baykan M., Erem C., Durmus I., Hacihasanoglu A., et al. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients. a randomized controlled study. Int J Obes Relat Metab Disord 28 (2004) 378-383
29. Grassi G., Seravalle G., Colombo M., Bolla G., Cattaneo B.M., Cavagnini F., et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 97 (1998) 2037-2042
30. Reisin E., Abel R., Modan M., Silverberg D.S., Eliahou H.E., and Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 298 (1978) 1-6